Timing Shift in Large-Scale Project Orders and Sluggish Execution of Customer Budgets
First written in FY2019-Q1. 15 of 19 entries say "Materialised", first in FY2019-Q1. Latest entry: 2026-05-13.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2018, the same year as the typical company in this theme.
The whole theme swung hardest in 2023: 5 of 8 companies on the "Worse" side.
7 other companies' latest entry also says "Materialised".
- FY2026-H1MaterialisedAnnual report
「The Life Science Research Support Services business declined because large projects shifted to the third quarter and beyond, while sales also declined because large projects from food companies entered a gap period. Overall, the business declined.」
The shifting of large pharmaceutical projects to a different fiscal period and the gap period between large projects from food companies were reflected in the results as a decline in revenue from Life Science Research Support Services. - FY2025-H1MaterialisedAnnual report
「In the US and Europe, orders struggled in both academia and pharmaceuticals, and the recording of sales was also delayed, resulting in a substantial decline in sales across the region.」
Weak orders and delays in recognizing revenue in Europe and the United States were reflected in the results as a substantial decline in sales across the region. In Japan, sales increased due to orders received ahead of schedule and the acquisition of large projects. - FY2024MaterialisedAnnual report
「In Japan, sales declined mainly in the academia and pharmaceutical fields. In academia, the special demand from supplementary budgets during the COVID-19 pandemic disappeared, while in pharmaceuticals, the end of large projects was a major factor.」
The disappearance of special demand in academia from supplementary budgets and the completion of large pharmaceutical projects were reflected in the results as a decline in revenue in the Advanced R&D Support Business. - FY2024-Q3MaterialisedAnnual report
「In this business segment, sales increased in the domestic food and chemical fields, but declined in academia and pharmaceuticals due to a decrease in large-scale human studies and other factors.」
The decrease in large-scale human studies was reflected in the results as a decline in sales in the academia and pharmaceutical fields. - FY2024-Q2MaterialisedAnnual report
「This was mainly due to the absence of sales from projects similar to the large project recorded in the same period of the previous year, primarily in domestic academia.」
Projects similar to the large project recorded in the same period of the previous year did not arise in domestic academia, and this was again reflected in the results as a factor behind the decline in revenue in the Advanced R&D Support Business. - FY2023MitigatedAnnual report
「As a result, the order backlog in the Advanced R&D Support Business was ¥427.910 million at the end of the current consolidated fiscal year, compared with ¥398.361 million at the end of the previous consolidated fiscal year.」
After order postponements and delays in obtaining samples had become apparent in the past, the order backlog increased from ¥398.361 million to ¥427.910 million, indicating that the recovery in orders continued. - FY2022MitigatedAnnual report
「As a result, the order backlog in the Advanced R&D Support Business was ¥398.361 million at the end of the current consolidated fiscal year, compared with ¥199.325 million at the end of the previous consolidated fiscal year.」
Following the order postponements and delays in obtaining samples that became apparent in the previous fiscal year, the order backlog increased from ¥199.325 million to ¥398.361 million, indicating a recovery in orders. - FY2022-Q2MitigatedAnnual report
「As a result of these activities, orders increased substantially from October, after the fourth state of emergency was lifted, and sales in the second quarter of the consolidated fiscal year, from October to December, reached the highest level in the Company's history.」
Following the order postponements and delays in obtaining samples that had become apparent through the previous fiscal year, orders increased substantially from October and quarterly sales reached a record high. - FY2022-Q1MaterialisedAnnual report
「Although most of the first quarter was under a state of emergency, orders remained firm. However, sales declined substantially year on year during the first quarter of the current consolidated fiscal year due to delays in obtaining measurement samples and other factors under the state of emergency.」
Although orders remained firm, delays in obtaining measurement samples under the state of emergency were reflected in the results as a substantial decline in sales. - FY2021MaterialisedAnnual report
「During the consolidated fiscal year, delays in research plans, including large-scale human studies, resulted in scheduled orders being postponed, and orders declined from the previous consolidated fiscal year.」
Delays in research plans and the postponement of scheduled orders were reflected in the full-year results as declines in orders received and the order backlog. - FY2021-Q3MaterialisedAnnual report
「During the third quarter of the current consolidated fiscal year, both orders and sales declined due to the postponement of scheduled orders and delays in obtaining measurement samples. Sales also declined during the first nine months of the current consolidated fiscal year.」
The postponement of scheduled orders and delays in obtaining measurement samples were reflected in the results as declines in orders and sales. - FY2020MitigatedAnnual report
「In the metabolomics business, the recovery in orders continued from the previous consolidated fiscal year, and the order backlog at the end of the consolidated fiscal year was ¥324.950 million, compared with ¥266.674 million at the end of the previous consolidated fiscal year.」
After the risks from the absence of large projects and weak orders in the first half became apparent in the previous fiscal year, a recovery in orders and an increase in the order backlog were reported. - FY2019MaterialisedAnnual report
「During the consolidated fiscal year, because there were no large orders comparable to those received in the same period of the previous year and order intake in the first half was sluggish, among other factors, revenue was ¥988,986 thousand and segment profit was ¥232,903 thousand.」
While the absence of large orders and sluggish order intake in the first half affected full-year performance, order intake began to recover from the second half, and the order backlog increased to ¥266,674 thousand. - FY2019-Q3MaterialisedAnnual report
「However, during the fourth quarter of the current consolidated fiscal year, because there were no large orders comparable to those received in the same period of the previous year and order intake in the first half was sluggish, among other factors, revenue was ¥834,095 thousand and segment profit was ¥238,748 thousand.」
The company stated that the continuing absence of large orders and sluggish order intake in the first half affected the performance of the metabolomics business. - FY2019-Q2MaterialisedAnnual report
「However, during the cumulative consolidated third quarter, revenue was ¥438.646 million, down 15.5% year on year, and segment profit was ¥18.997 million, down 87.7%, due mainly to the absence of large orders such as those received in the same period of the previous year and sluggish order intake in the first half.」
The continuing absence of large orders and sluggish order intake in the first half were reflected in the results as lower revenue and a 87.7% decline in segment profit. - FY2019-Q1MaterialisedAnnual report
「However, during the cumulative consolidated second quarter, revenue was ¥276.414 million, down 10.1% year on year, and segment profit was ¥5.947 million, down 91.1%, due mainly to the absence of large orders such as those received in the same period of the previous year and sluggish customer budget execution.」
The absence of large orders comparable to those received in the same period of the previous year, as large-order bookings shifted to the second half or later, together with sluggish customer budget execution, was reflected in lower revenue and profit for the quarter.